ACP
LEGN icon

Altitude Crest Partners’s Legend Biotech LEGN Stock Holding History

Altitude Crest Partners’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-652,732
Closed -$36.6M – 19
2024
Q1 		$36.6M Buy
652,732
+110,916
+20% +$6.69M 15.67% 1
2023
Q4 		$32.6M Buy
+541,816
New +$34.3M 21.82% 1

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Altitude Crest Partners's LEGN Position: Q2 2024 in Review

Altitude Crest Partners sold out of Legend Biotech (LEGN) in Q2 2024, closing a stake of 652,732 shares — an estimated $36.6M sold.

Altitude Crest Partners first reported a position in LEGN in Q4 2023 and held it in 2 quarters. The position peaked at $36.6M in Q1 2024. 180 funds tracked by Wall St. Rank hold LEGN as of Q2 2024.

  • Altitude Crest Partners reported no remaining Legend Biotech position as of Q2 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 652,732 Legend Biotech shares in Q2 2024, an estimated $36.6M.
  • Altitude Crest Partners first reported a position in Legend Biotech in Q4 2023 and held it in 2 quarters.
  • Altitude Crest Partners's Legend Biotech position peaked at $36.6M in Q1 2024.
  • 180 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.